Pages that link to "Q3995913"
Jump to navigation
Jump to search
The following pages link to tositumomab (Q3995913):
Displayed 50 items.
- Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. (Q33360413) (← links)
- Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab (Q33368796) (← links)
- Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma (Q33369640) (← links)
- Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study (Q33389503) (← links)
- Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma (Q33915986) (← links)
- R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. (Q33934326) (← links)
- Tositumomab and iodine I 131 tositumomab (Bexaar). (Q34173204) (← links)
- Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. (Q34386601) (← links)
- Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members (Q34485807) (← links)
- Bexxar (Corixa/GlaxoSmithKline). (Q34675515) (← links)
- Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma. (Q34789358) (← links)
- A clinical and scientific overview of tositumomab and iodine I 131 tositumomab (Q35120247) (← links)
- The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab (Q35120249) (← links)
- Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma (Q35641192) (← links)
- Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma (Q35718922) (← links)
- Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications (Q35952444) (← links)
- Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view (Q36004574) (← links)
- Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. (Q36011303) (← links)
- Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. (Q36054254) (← links)
- A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma (Q36150468) (← links)
- Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas (Q36489856) (← links)
- Iodine-131 tositumomab (Bexxar) in a radiation oncology environment (Q36595686) (← links)
- Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma (Q36839758) (← links)
- Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma (Q37290469) (← links)
- Radioimmunotherapy of lymphoma: Bexxar and Zevalin (Q37683833) (← links)
- Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis (Q39954455) (← links)
- Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab (Q40227442) (← links)
- Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas (Q40624994) (← links)
- Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation (Q41935347) (← links)
- Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens (Q43512472) (← links)
- A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 (Q44435109) (← links)
- Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma (Q45144762) (← links)
- Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma (Q46658491) (← links)
- Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. (Q46706714) (← links)
- Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma. (Q48026939) (← links)
- Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine(131)-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma (Q48085778) (← links)
- Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma (Q48260192) (← links)
- Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy. (Q51033770) (← links)
- CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. (Q53173591) (← links)
- Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. (Q53251676) (← links)
- Iodine-131 Tositumomab(Bexxar) in relapsed/refractory non-Hodgkin's lymphoma: update from the 2001 American Society of Hematology meeting. (Q53973079) (← links)
- Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. (Q55709954) (← links)
- Itolizumab (Alzumab), Mogamulizumab (Poteligeo), and Tositumomab (Bexxar) (Q58008014) (← links)
- Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab, and Votumumab (Q58008154) (← links)
- Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma (Q61918562) (← links)
- A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) (Q63316197) (← links)
- Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma (Q63320310) (← links)
- Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. (Q64949008) (← links)
- Bexxar rejected for now (Q73037139) (← links)
- Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report (Q73100455) (← links)